Implication of nigral tachykinin NK 3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: A pharmacologic and autoradiographic study

British Journal of Pharmacology

Volumn 138, Issue 4, 2003, Pages 554-563

  Lessard, Andrée ^a   Campos, Maria M ^a   Neugebauer, Witold ^b   Couture, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Central autonomic regulation; Hypertension; NK 1; NK 2 and NK 3 receptors; Substantia nigra; Tachykinins

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; IODINE 125; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR AGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROKININ A [4-10][8 BETA ALANINE]; OSANETANT; R 820; SAREDUTANT; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; BLOOD VESSEL TONE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HEART RATE; HIPPOCAMPUS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MESENCEPHALON; MICROINJECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR AFFINITY; SUBSTANTIA NIGRA; TACHYCARDIA; VENTRAL TEGMENTUM;

ANIMALS; AUTORADIOGRAPHY; BLOOD PRESSURE; HEART RATE; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, NEUROKININ-3; SUBSTANTIA NIGRA;

EID: 0037294126     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705042     Document Type: Article

References (53)

1. 2) receptor revisited with SR 48968, a potent non peptide antagonist. Biochem. Biophys. Res. Commun., 184, 1418-1424.
2. BANNON, M.J. & WHITTY, C.J. (1995). Neurokinin receptor gene expression in substantia nigra: localization, regulation, and potential physiological significance. Can. J. Physiol. Pharmacol., 73, 866-870.
3. BARBEAU, A., GILLO-JOFFROY, L., BOUCHER, R., NOWACZYNSKI, W. & GENEST, J. (1969). Renin-aldosterone system in Parkinson's disease. Science, 165, 291-292.
4. 1 receptor antagonists in the rat. Br. J. Pharmacol., 127, 717-728.
5. 3 receptor antagonists in the conscious rat. Br. J. Pharmacol., 122, 643-654.
6. CELLIER, E. & COUTURE, R. (1997). Mechanism of cardiovascular and behavioural responses to central NK-3 receptor activation in conscious rat. In Tachykinins in Health and Disease, International Tachykinin Conference, Cairns (Australia), September 7-11, Abstract book, p. 40.
7. 3): a double immunocytochemical study in the rat. Brain Res., 780, 150-154.
8. COUTURE, R., TOMA, N. & BARBOT, L. (2000). SR142801 behaves as a tachykinin NK-3 receptor agonist on a spinal nociceptive reflex in the rat. Life Sci., 66, 51-65.
9. CULMAN, J., KLEE, S., OHLENDORF, C. & UNGER, Th. (1997). Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther., 280, 238-246.
10. CULMAN, J. & UNGER, Th. (1995). Central tachykinins: mediators of defence reaction and stress reactions. Can. J. Physiol. Pharmacol., 73, 885-891.
11. 3H]senktide. Brain Res., 506, 175-179.
12. DE CHAMPLAIN, J. (1998). Participation du système nerveux autonome dans l'hypertension artérielle. Médecine Sciences, 14 (Suppl. 2), 10-22.
13. 3 receptor. Life Sci., 56, PL27-PL32.
14. EMONDS-ALT, X., VILAIN, P., GOULAOUIC, P., PROIETTO, V., VAN BROECK, D., ADVENIER, C., NALINE, E., NELIAT, G., LE FUR, G. & BRELIÈRE, J.-C. (1992). A potent and selective non peptide antagonist of the neurokinin A (NK-2) receptor. Life Sci., 50, PL101-PL106.
15. FUTAMI, T., HATANAKA, Y., MATSUSHITA, K. & FURUYA, S. (1998). Expression of substance P receptor in the substantia nìgra. Mol. Brain Res., 54, 183-198.
16. GARRET, C., CARRUETTE, A., FARDIN, V., MOUSSAOUI, S., PEYRONEL, J.-F., BLANCHARD, J.-C. & LADURON, P.M. (1991). Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc. Natl. Acad. Sci. U.S.A., 88, 10208-10212.
17. GRASSI, G., CATTANEO, B.M., SERAVALLE, G., LANFRANCHI, A. & MANCIA, G. (1998). Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension, 31, 68-72.
18. HELKE, C.J., KRAUSE, J.E., MANTYH, P.W., COUTURE, R. & BANNON, M.J. (1990). Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J., 4, 1606-1615.
19. HUMPEL, C. & SARIA, A. (1989). Effects of GABA and L-glutamic acid on the potassium-evoked in vitro release of substance P and neurokinin A-like immunoreactivities are different in the rat striatum and substantia nigra. Neurosci. Lett., 105, 159-163.
20. HUMPEL, C. & SARIA, A. (1993). Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat. Neurosci. Lett., 157, 223-226.
21. HUMPEL, C., SARIA, A. & REGOLI, D. (1991). Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism. Eur. J. Pharmacol., 195, 107-114.
22. HUNTER, W.M. & GREENWOOD, F.C. (1962). Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature, 194, 495-496.
23. ITOI, K., TSCHÖPE, C., JOST, N., CULMAN, J., LEBRUN, C., STAUSS, B. & UNGER, T.H., (1992). Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioural responses in conscious rats. Eur. J. Pharmacol., 219, 435-444.
24. JESSEL, T.M. (1978). Substance P release from the rat substantia nigra. Brain Res., 151, 469-478.
25. JULIUS, S. (1988). The blood pressure seeking properties of the central nervous system. J. Hypert., 6, 177-185.
26. KIROUAC, G.J. & GANGULY, P.K. (1993). Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic analysis. Neuroscience, 52, 135-141.
27. KORNER, P.I. (1989). Baroreceptor resetting and other determinants of baroreflex properties in hypertension. Clin. Exp. Pharmacol. Physiol., 15 (Suppl), 45-64.
28. LANGLOIS, X., WINTMOLDERS, C., RIELE, P., LEYSEN, J.E. & JURZAK, M. (2001). Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacol., 40, 242-253.
29. LESSARD, A. & COUTURE, R. (2001). Modulation of cardiac activity by tachykinins in the rat substantia nigra. Br. J. Pharmacol., 134, 1749-1759.
30. LIN, M.-T. & YANG, J.-J. (1994). Stimulation of the nigrostriatal dopamine system produces hypertension and tachycardia in rats. Am. J. Physiol. (Heart Circ. Physiol. 35), 266, H2489-H2496.
31. LINDEFORS, N., BRODIN, E., TOSSMAN, U., SEGOVIA, J. & UNGERSTEDT, U. (1989). Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Expl. Brain Res., 74, 527-534.
32. LINTHORST, A.C.E., VAN GIERSBERGEN, P.L.M., GRAS, M., VERSTEEG, D.H.G. & DE JONG, W. (1994). The nigrostriatal dopamine system: role in the development of hypertension in spontaneously hypertensive rats. Brain Res., 639, 261-268.
33. 3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides, 32, 481-488.
34. MICIELI, G., MARTIGNONI, E., CAVALLINI, A., SANDRINI, G. & NAPPI, G. (1987). Postprandial and orthostatis hypotension in Parkinson's disease. Neurology, 37, 386-393.
35. NALIVAIKO, E., MICHAUD, J.-C., SOUBRIÉ, P., LE FUR, G. & FELTZ, P. (1997). Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience, 78, 745-757.
36. PAXINOS, G. & WATSON, C. (1998). The Rat Brain in Stereotaxic Coordinates. 4th edn. California, USA: Academic Press, San Diego.
37. PICARD, P., REGOLI, D. & COUTURE, R. (1994). Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br. J. Pharmacol., 112, 240-249.
38. REGOLI, D., DRAPEAU, G., DION, S. & COUTURE, R. (1988). New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol. Sci., 9, 290-295.
39. REGOLI, D., NGUYEN, Q.T. & JUKIC, D. (1994). Neurokinin receptor subtypes characterized by biological assays. Life Sci., 54, 2035-2047.
40. REID, M.S., HERRERA-MARSCHITZ, M., HÖKFELT, T., LINDEFORS, N., PERSSON, H. & UNGERSTEDT, U. (1990). Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp. Brain Res., 82, 293-303.
41. RIBEIRO-DA-SILVA, A., MCLEOD, A.L. & KRAUSE, J.E. (2000). Neurokinin receptors in the CNS. In Handbook of Chemical Neuroanatomy. Vol. 16, Part I, Peptide Receptors. eds. Quirion, R., Björklund, A., Hökfelt, T. pp 195-240. Amsterdam: Elsevier Science B.V.
42. ROVERO, P., PESTILLINI, V., PATACCHINI, R., GIULIANI, S., SANTICIOLI, P., MAGGI, C.A., MELI, A. & GIACHETTI, A. (1989). A potent and selective agonist for the NK-2 tachykinin receptor. Peptides, 10, 593-595.
43. SHUGHRUE, P.J., LANE, M.V. & MERCHENTHALER, I. (1996). In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J. Comp. Neurol., 372, 395-414.
44. SIVAM, S.P. & KRAUSE, J.E. (1992). Tachykinin systems in the spinal cord and basal ganglia: influence of neonatal capsaicin treatment or dopaminergic intervention on levels of peptides, substance P-encoding mRNAs, and substance P receptor mRNA. J. Neurochem., 59, 2278-2284.
45. STOESSL, A.J. (1994). Localization of striatal and nigral tachykinin receptors in the rat. Brain Res., 646, 13-18.
46. STOESSL, A.J., BRACKSTONE, M., RAJAKUMAR, N. & GIBSON, C.J. (1995). Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Res., 700, 115-120.
47. 3H]senktide. Brain Res., 534, 1-7.
48. UNGER, Th., CAROLUS, S., DEMMERT, G., GANTEN, D., LANG, R.E., MASER-GLUTH, C., STEINBERG, H. & VEELKEN, R. (1988). Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ. Res., 63, 812-820.
49. UNGER, Th., ROCKHOLD, R.W., YUKIMURA, T., RETTIG, R. & GANTEN, D. (1980). Blood pressure and heart rate responses to centrally administered substance P are increased in spontaneously hypertensive rats. Clin. Sci., 59, 299s-302s.
50. VAN DEN BUUSE, M., LINTHORST, A.C.E., VERSTEEG, D.H.G. & DE JONG, W. (1991). Role of brain dopamine systems in the development of hypertension in the spontaneously hypertensive rat. Clin. Exp. Hyp., A13, 653-659.
51. WHITTY, C.J., WALKER, P.D., GOEBEL, D.J., POOSCH, M.S. & BANNON, M.J. (1995). Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience, 64, 419-425.
52. WÖRMSER, U., LAUFER, R., HART, Y., CHOREV, M., GILON, C. & SELINGER, Z. (1986). Highly selective agonists for substance P receptor subtypes. EMBO J., 5, 2805-2808.
53. YUAN, Y.D. & COUTURE, R. (1997). Renal effects of intracerebroventricularly injected tachykinins in the conscious saline-loaded rat: receptor characterization. Br. J. Pharmacol., 120, 785-796.